Jump to main content
Jump to site search

Issue 35, 2017
Previous Article Next Article

Halogen bonded cocrystals of active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline in combination with haloperfluorinated compounds

Author affiliations

Abstract

In this work, we present the cocrystallization of three model active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline. As cocrystal coformers, we selected perfluorinated halogen bond donors, 1,4-diiodotetrafluorobenzene (tfib) and 1,4-dibromotetrafluorobenzene (tfbb). From a crystal engineering standpoint, the compounds are interesting due to the presence of various potential donor and acceptor species. The choice of structurally equivalent, ditopic linear halogen bond donors, although of different donor strength, allowed us to study the competition between hydrogen and halogen bonding in the obtained solids. We have prepared six cocrystals by both mechanochemical synthesis and a conventional solution-based method. The results of our work show that the dominant supramolecular bond in pyrazinamide cocrystals is the X⋯N type halogen bond (where X = Br or I) established with the pyrazinyl nitrogen atom, in lidocaine cocrystals it is the X⋯O type halogen bond, while in pentoxifylline cocrystals it is dependent on the donor strength. In the tfib cocrystals, halogen bonds are established with both the secondary nitrogen atom and the xanthyl oxygen atom, while in the tfbb cocrystals only Br⋯O halogen bonds are formed.

Graphical abstract: Halogen bonded cocrystals of active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline in combination with haloperfluorinated compounds

Back to tab navigation

Supplementary files

Publication details

The article was received on 06 Jul 2017, accepted on 02 Aug 2017 and first published on 02 Aug 2017


Article type: Paper
DOI: 10.1039/C7CE01252G
Citation: CrystEngComm, 2017,19, 5293-5299
  •   Request permissions

    Halogen bonded cocrystals of active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline in combination with haloperfluorinated compounds

    D. Choquesillo-Lazarte, V. Nemec and D. Cinčić, CrystEngComm, 2017, 19, 5293
    DOI: 10.1039/C7CE01252G

Search articles by author

Spotlight

Advertisements